Skip to main content

Table 4 Comparison of early poxvirus-induced immune responses to selected innate molecular signatures of existing vaccine vectors. Differences in Log2 Fold Changes (between each virus and the control) are depicted

From: Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model

 

description

MVA

LSDV

CNPV

FWPV

PEPV

FeP2

Evidence

References

Innate immune response

        

Pathogen recognition

        

Tlr13

toll-like receptor 13

1.4

1.0

1.7

1.5

1.0

-

  

Tlr3

toll-like receptor 3

1

1.4

1.2

1.1

-

-

Merck Ad5/HIV

[22]

Tlr7

toll-like receptor 7

1.1

1.2

1.2

-

-

-

YF-17D, LAIV

[20, 21]

Tlr8

toll-like receptor 8

1.1

1.1

1.3

1.0

-

-

Merck Ad5/HIV

[22]

Tlr11

toll-like receptor 11

−1.0

-

-

-

-

-

  

Ddx58 (RIG-I)

RIG-I-like receptor

-

1.3

-

-

-

-

YF-17D

[20]

Cd209a (DC SIGN)

CD209a antigen

−1.7

−2.2

−1.1

−1.5

-

-

  

Cd209b (DC SIGN)

CD209b antigen

−1.2

−1.3

-

-

-

-

  

Ifih1 (MDA5)

RIG-I-like receptor

1.3

2.1

1.2

1.2

-

-

YF-17D

[20]

Zbp1 (DAI)

cytoplasmic double-stranded DNA sensor

1.9

2.7

1.3

1.6

-

-

  

Dhx58 (LGP2)

RIG-I-like receptor

1.7

2.5

1.6

1.5

-

-

YF-17D

[20]

Eif2ak2 (PKR)

eukaryotic translation initiation factor 2-alpha kinase 2 (protein kinase R)

1.1

2.1

1.1

1.1

-

-

YF-17D

[20]

Genes associated with the innate immune response of viral vectors

Cxcl10 (IP-10)

chemokine (C-X-C motif) ligand 10

2.7

3

2.2

2.8

1.7

-

Significantly upregulated in response to YF-17D, Merck Ad5/HIV, TIV

[20−22]

Mx1

myxovirus (influenza virus) resistance 1

3.2

3.9

3

2.8

-

-

YF-17D

[20]

Il-1α

interleukin 1 alpha

1.9

2

2.2

2.3

1.8

-

Significantly upregulated in response to YF-17D

 

Isg15

ISG15 ubiquitin-like modifier

1.6

2.2

1.5

1.4

-

-

Merck Ad5/HIV

[22]

Stat1

signal transducer and activator of transcription 1

-

1.4

-

-

-

-

YF-17D, Merck Ad5/HIV, LAIV

[20−22]

Cxcl11 (I-TAC)

chemokine (C-X-C motif) ligand 11

4.5

4.4

3.4

4.3

1.5

-

Merck Ad5/HIV

[22]

Ccr5

chemokine (C-C motif) receptor 5

1.1

1.5

1.3

1.3

-

-

Merck Ad5/HIV

[22]

Gbp7

guanylate binding protein 7

1.6

2.2

1.2

1.7

-

-

Merck Ad5/HIV

[22]

Irf1

interferon regulatory factor 1

-

1.3

-

1.1

-

-

Merck Ad5/HIV

[22]

Stat2

signal transducer and activator of transcription 2

1.4

1.9

1.2

1.5

-

-

LAIV

[21]

Irf7

interferon regulatory factor 7

1.7

2.9

1.7

1.1

-

-

LAIV

[21]

Casp1

caspase 1

1.1

-

1.2

1.1

-

-

  

Adaptive immune response

B cell related responses

Ighg

Immunoglobulin heavy chain (gamma polypeptide)

-

-

1.5

1.6

-

-

  

Ighg3

Immunoglobulin heavy constant gamma 3

-

-

1.3

1.2

-

-

TIV, correlated with decreased risk of HIV-1 infection in the RV144 trial ALVAC-HIV(vCP1521)

 

Ighm

immunoglobulin heavy constant mu

-

-

1.1

-

-

-

positively correllates with antibody response to TIV

[21]

Igk

immunoglobulin kappa chain complex

-

−1.0

-

-

-

-

positively correllates with antibody response to TIV

[21]

T cell related responses

Gzmb

granzyme B

3.7

4.7

4.1

4.2

2.4

-

expressed by CD8+ T cells in response to YF-17D

[20]

Ccr5

chemokine (C-C motif) receptor 5

1.1

1.5

1.3

1.3

-

-

expressed by CD8+ T cells in esponse to YF-17D

[20]

Ccl2 (MCP1)

chemokine (C-C motif) ligand 2

3.5

3.3

2.9

3.3

2.8

-

predicted the magnitude of the CD8+ T cell response to Merck Ad5/HIV

[22]

  1. HIV human immunodeficiency virus, LAIV live attenuated influenza vaccine, TIV trivalent influenza vaccine, YF-17D Yellow fever vaccine, Merck Ad5/HIV Merck’s Adenovirus subtype 5-based HIV vaccine
Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us